Skip to main content
SpringerLink
Log in

Lipids

  • Chapter
  • First Online:
Handbook of Outpatient Medicine

  • 512 Accesses

Abstract

Hyperlipidemia is a common medical condition encountered in the ambulatory setting. It is one of the risk factors for cardiovascular disease. Therefore, screening for and treating hyperlipidemia are of critical importance in primary and secondary prevention of cardiovascular events. The 2019 ACC/AHA guidelines promote treating lipid disorders according to a patient’s overall risk of atherosclerotic cardiovascular disease, instead of treating to a target LDL goal as recommended by previous guidelines. Statins remain the first-line therapy for hyperlipidemia and have consistently been shown to reduce cardiovascular events and mortality. Other medications, including Ezetimibe and PCSK 9 inhibitors, should be considered in treating high-risk patients with suboptimal response or intolerance to statins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chait A, Brunzell JD. Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinol Metab Clin N Am. 1990;19(2):259–78.

    Article  CAS  Google Scholar 

  2. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823–8.

    Article  CAS  Google Scholar 

  3. Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation. 2013;127(6):749–56.

    Article  Google Scholar 

  4. Zak A, et al. Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(2):181–8.

    Article  Google Scholar 

  5. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143–421.

    Article  Google Scholar 

  6. Martin SS, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310(19):2061–8.

    Article  CAS  Google Scholar 

  7. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation. 2008;118(20):2047–56.

    Article  CAS  Google Scholar 

  8. Doran B, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation. 2014;130(7):546–53.

    Article  CAS  Google Scholar 

  9. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;140(11):e596–646.

    Google Scholar 

  10. Stone NJ, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.

    Google Scholar 

  11. Eckel RH, et al. AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2960–84.

    Article  Google Scholar 

  12. Fowkes FG, et al. Development and validation of an ankle brachial index risk model for the prediction of cardiovascular events. Eur J Prev Cardiol. 2014;21(3):310–20.

    Article  CAS  Google Scholar 

  13. Polonsky TS, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303(16):1610–6.

    Article  CAS  Google Scholar 

  14. Ranthe MF, et al. A detailed family history of myocardial infarction and risk of myocardial infarction—a nationwide cohort study. PLoS One. 2015;10(5):e0125896.

    Article  Google Scholar 

  15. Ridker PM, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243–51. 4p following 2251

    Article  CAS  Google Scholar 

  16. Bilheimer DW, et al. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A. 1983;80(13):4124–8.

    Article  CAS  Google Scholar 

  17. Bruckert E, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.

    Article  CAS  Google Scholar 

  18. Finegold JA, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21(4):464–74.

    Article  Google Scholar 

  19. Thompson PD, et al. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.

    Article  CAS  Google Scholar 

  20. Cohen DE, et al. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97(8A):77C–81C.

    Article  CAS  Google Scholar 

  21. Swerdlow DI, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomized trials. Lancet. 2015;385(9965):351–61.

    Article  CAS  Google Scholar 

  22. Elam MB, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2(4):370–80.

    Article  Google Scholar 

  23. Keech A, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005;366(9500):1849–61.

    Article  CAS  Google Scholar 

  24. Blais JE, et al. Comparative efficacy and safety of statin and fibrate monotherapy: a systematic review and meta-analysis of head-to-head randomized controlled trials. PLoS One. 2021;16(2):e0246480.

    Article  CAS  Google Scholar 

  25. Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380:11–22.

    Article  CAS  Google Scholar 

  26. Cannon CP, et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). N Engl J Med. 2015;372(25):2387–97.

    Article  CAS  Google Scholar 

  27. Writing C, et al. ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2016;68(1):92–125.

    Google Scholar 

  28. Robinson JG, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99.

    Article  CAS  Google Scholar 

  29. Sabatine MS, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–9.

    Article  CAS  Google Scholar 

  30. Ray KK, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507–19.

    Article  CAS  Google Scholar 

  31. Goldberg AC, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Jacobi Medical Center, Bronx, NY, USA

    Anjali Manavalan

Authors
  1. Anjali Manavalan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anjali Manavalan .

Editor information

Editors and Affiliations

  1. Department of Medicine, Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, USA

    Elana Sydney

  2. Department of Medicine, Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, USA

    Eleanor Weinstein

  3. Department of Medicine, Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, USA

    Lisa M. Rucker

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Manavalan, A. (2022). Lipids. In: Sydney, E., Weinstein, E., Rucker, L.M. (eds) Handbook of Outpatient Medicine. Springer, Cham. https://doi.org/10.1007/978-3-031-15353-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-15353-2_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-15352-5

  • Online ISBN: 978-3-031-15353-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation